GLP-1 weight loss claims on TikTok: what the data says

What did @ladymax322 actually say?

In a short clip with 327,000+ views, @ladymax322 made two claims: that Ozempic is "proven to lower A1C" and that "most people who took Ozempic reached an A1C under 7." The first part is well-supported. The second part is where things get complicated, and the lack of any context around who those people were matters more than the creator probably realized.

To be fair, she's not making anything up from thin air. There are clinical trials showing strong A1C reductions with semaglutide. But "most people" reaching under 7 is a number that depends heavily on the population studied, the baseline A1C, the dose used, and how long people stayed on the medication. Dropping that context in a TikTok clip with no caveats is the kind of thing that sets unrealistic expectations for the 38 million Americans living with type 2 diabetes.

Does the science back this up?

Partially, yes. The SUSTAIN trial program, which ran across multiple studies published between 2016 and 2018 in journals including The Lancet Diabetes and Endocrinology, showed semaglutide 0.5 mg and 1 mg reduced A1C by roughly 1.0 to 1.8 percentage points versus placebo. That is genuinely significant.

The SUSTAIN-6 trial (Marso et al., 2016, NEJM) found A1C reductions of about 1.0 percentage point with semaglutide 0.5 mg and 1.4 points with 1 mg. In SUSTAIN-7 (Pratley et al., 2018, Lancet Diabetes and Endocrinology), 66% to 79% of patients on semaglutide 1 mg reached A1C below 7%, compared to 52% to 60% on dulaglutide. So yes, in that specific trial, with that specific dose, in a managed clinical setting, "most people" is defensible. But the real world is messier than a randomized controlled trial.

What did they get wrong (or right)?

The first claim, that Ozempic is "proven to lower A1C," is accurate. That part deserves credit. The FDA approved semaglutide for type 2 diabetes management in 2017 specifically because of this evidence base.

The second claim, that "most people" hit under 7%, is where the video oversimplifies. The studies showing that outcome enrolled patients who were consistently medicated, closely monitored, and often had moderate rather than severely elevated baseline A1C values. Real-world adherence data tells a different story. A 2022 analysis in Diabetes Care (Bain et al.) found that roughly 50% of GLP-1 receptor agonist users discontinue within 12 months, which directly affects glycemic outcomes. Someone who stops Ozempic because of nausea or cost is not going to sustain the A1C improvement seen in trials.

The video also uses the nonstandard spelling "O'Zempic," which is a minor but telling signal that precision is not the priority here.

What should you actually know?

Semaglutide does lower A1C. That is not in dispute. But the "most people reach under 7" framing strips away everything that determines whether that outcome is realistic for any individual: their starting A1C, their dose, how long they take it, what else they are doing for blood sugar management, and whether they can afford to stay on it long-term.

A1C under 7% is the American Diabetes Association's general target for many adults with type 2 diabetes. Reaching it with semaglutide is possible, and for patients in the SUSTAIN trial with moderate baseline A1C, likely. But patients starting at A1C of 10% or higher face a steeper climb. And Ozempic is not the only variable. Diet, activity, other medications, and kidney function all factor in.

If you saw this video and thought Ozempic is a guaranteed ticket to A1C under 7, talk to a clinician before drawing that conclusion. The drug is effective. The claim as stated is too absolute.